AN2 Therapeutics (ANTX)

• Market cap: $33.2M
• 1 day: 1.83%
• 5 days: -10.48%
• 1 month: -19.57%
• 3 months: 2.78%
• 6 months: -55.78%
• Year to date: -20.14%
• 1 year: -94.71%
• 5 years: -92.79%
• 10 years: -92.79%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Employees: 36

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

20.19% less ownership

Funds ownership: 65.48% [Q2] → 45.29% (-20.19%) [Q3]

30% less funds holding

Funds holding: 46 [Q2] → 32 (-14) [Q3]

59% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 22

66% less capital invested

Capital invested by funds: $42M [Q2] → $14.5M (-$27.5M) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 350% upside
• Avg. target: $5 350% upside
• High target: $5 350% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

JMP Securities Roy Buchanan 37% 1-year accuracy 7 / 19 met price target

350% upside $5

Market Outperform Reiterated

3 Feb 2025